StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
DelistingJul 24, 2026, 04:08 PM

Invivyd Receives Nasdaq Delisting Notice for Bid Price

AI Summary

Invivyd, Inc. received a deficiency letter from Nasdaq on July 23, 2026, notifying the company that its common stock had traded below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days. Failure to comply could lead to delisting, though an additional 180-day period may be available under certain conditions.

Key Highlights

  • Invivyd received a deficiency letter from Nasdaq on July 23, 2026.
  • Common stock bid price closed below $1.00 for 30 consecutive business days.
  • Company has until January 19, 2027, to regain compliance with the Minimum Bid Price Requirement.
  • To comply, closing bid price must be at least $1.00 for 10 consecutive business days.
  • May be eligible for an additional 180-day period if transferred to Nasdaq Capital Market.
  • Company intends to monitor bid price and consider options to resolve the deficiency.